The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)

Interventions for valvular disease and heart failure

Transapical transcatheter mitral valve implantation in patients with prior aortic valve replacement: a feasibility report

EuroIntervention 2021;17:257-259. DOI: 10.4244/EIJ-D-19-00947

1. University Hospital of Zurich, University of Zurich, Zurich, Switzerland; 2. Minneapolis Heart Institute Foundation at Abbott Northwestern Hospital, Minneapolis, MN, USA; 3. Department of Cardiothoracic Surgery, Oslo University, Oslo, Norway; 4. Clinique Pasteur, Toulouse, France; 5. University Heart Center, Hamburg, Germany; 6. Cardiovascular Surgery Department, Cœur Poumon CHU de Lille, Lille, France; 7. Heart Center Bonn, University Hospital, Bonn, Germany; 8. Emory Structural Heart and Valve Center, Atlanta, GA, USA; 9. Cardiance Clinic, Pfäffikon, Switzerland; 10. University of Bern, Bern, Switzerland
Introduction

Transcatheter mitral valve implantation (TMVI) has recently emerged as a treatment option for selected high-risk patients with symptomatic mitral regurgitation (MR).

Although the feasibility of TMVI in patients with previous aortic valve (AV) prostheses has been reported1, the interaction between a TMVI and an AV prosthesis has not previously been well characterised. In particular, the risk of left ventricular outflow tract (LVOT) obstruction after TMVI may be higher in patients with a pre-existing aortic valve prosthesis, due to the presence of concomitant LV hypertrophy. Moreover, the frame of the aortic prosthesis can extend into the LVOT, and ...

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Read next article
Outcomes of directional atherectomy for common femoral artery disease